1. Frequency of TERT promoter mutations in primary tumors of the liver.

    Virchows Archiv. A. Pathological Anatomy and Hi... 465(6):673 (2014) PMID 25267585

    Transcriptional regulation of the TERT gene is a major cause of the cancer-specific increase in telomerase activity. Recently, frequent somatic mutations in the TERT promoter have been described in several tumor entities such as melanoma, glioblastoma, bladder cancer, and hepatocellular carcinom...
  2. Frequency of TERT promoter mutations in primary tumors of the liver.

    Virchows Archiv. A. Pathological Anatomy and Hi... 465(6):673 (2014) PMID 25267585

    Transcriptional regulation of the TERT gene is a major cause of the cancer-specific increase in telomerase activity. Recently, frequent somatic mutations in the TERT promoter have been described in several tumor entities such as melanoma, glioblastoma, bladder cancer, and hepatocellular carcinom...
  3. Prognostic impact of perineural, blood and lymph vessel invasion for esophageal cancer.

    Histology and histopathology 29(11):1467 (2014) PMID 24819775

    With a median survival of ⟨22 months esophageal cancer is one of the most aggressive tumors, up to 20% of node negative patients develop systemic relapse. Studies investigating the prognostic impact of tumor-micro-invasion in blood (AI) and lymphatic vessels (LVI) as well as perineural invasion ...
  4. Prognostic impact of perineural, blood and lymph vessel invasion for esophageal cancer.

    Histology and histopathology 29(11):1467 (2014) PMID 24819775

    With a median survival of ⟨22 months esophageal cancer is one of the most aggressive tumors, up to 20% of node negative patients develop systemic relapse. Studies investigating the prognostic impact of tumor-micro-invasion in blood (AI) and lymphatic vessels (LVI) as well as perineural invasion ...
  5. Prognostic impact of perineural, blood and lymph vessel invasion for esophageal cancer.

    Histology and histopathology 29(11):1467 (2014) PMID 24819775

    With a median survival of ⟨22 months esophageal cancer is one of the most aggressive tumors, up to 20% of node negative patients develop systemic relapse. Studies investigating the prognostic impact of tumor-micro-invasion in blood (AI) and lymphatic vessels (LVI) as well as perineural invasion ...
  6. Prognostic impact of perineural, blood and lymph vessel invasion for esophageal cancer.

    Histology and histopathology 29(11):1467 (2014) PMID 24819775

    With a median survival of ⟨22 months esophageal cancer is one of the most aggressive tumors, up to 20% of node negative patients develop systemic relapse. Studies investigating the prognostic impact of tumor-micro-invasion in blood (AI) and lymphatic vessels (LVI) as well as perineural invasion ...
  7. Morphological study of synovial changes in two-stage reconstructions of the infected hip and knee arthroplasties.

    BMJ Open 2(4) (2012) PMID 22893669 PMCID PMC3425892

    To study the morphological changes of the regenerating synovium in two-stage revision arthroplasty, which is the gold standard for treatment of periprosthetic joint infection. The authors analysed a series of synovial biopsies to examine morphological changes in healing periprosthetic tissues da...
  8. Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer.

    Human Pathology 41(3):358 (2010) PMID 19896697

    Cell division cycle 7 is a widely expressed protein kinase implicated in cell division, cell cycle checkpoint mechanisms, and cancer progression. To determine the relationship of cell division cycle 7 protein expression with tumor phenotype, molecular features and prognosis, 2197 highly characte...
  9. Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer

    Human Pathology 41(3):358 (2010)

    Cell division cycle 7 is a widely expressed protein kinase implicated in cell division, cell cycle checkpoint mechanisms, and cancer progression. To determine the relationship of cell division cycle 7 protein expression with tumor phenotype, molecular features and prognosis, 2197 highly cha...
  10. HER-2 amplification is highly homogenous in gastric cancer.

    Human Pathology 40(6):769 (2009) PMID 19269014

    Her-2 is the molecular target for antibody-based treatment of breast cancer (trastuzumab). The potential benefit of anti-Her-2 therapy is currently investigated in several other HER-2-amplified cancers including gastric cancer. Although HER-2 amplification occurs in more than 10% of gastric canc...
  11. HER-2amplification is highly homogenous in gastric cancer

    Human Pathology 40(6):769 (2009)

    Her-2 is the molecular target for antibody-based treatment of breast cancer (trastuzumab). The potential benefit of anti–Her-2 therapy is currently investigated in several other HER-2–amplified cancers including gastric cancer. Although HER-2 amplification occurs in more than 10% of gastric...